Aimei Health Technology Co., Ltd. 8-K

What Happened

• Aimei Health Technology Co., Ltd. filed an 8‑K on Jan 6, 2026 (Item 2.03) announcing it deposited $34,330.96 into its public shareholders' trust account to extend the deadline to complete its initial business combination from Jan 6, 2026 to Feb 6, 2026. This is the fourteenth monthly extension permitted under the company’s Amended and Restated Articles of Association.
• To fund that Extension Payment, on Jan 5, 2026 the company issued an unsecured promissory note (principal $34,330.96) to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the “Payees”), split equally ($17,165.48 each). The note bears no interest and the principal is due when the company consummates a business combination with United Hydrogen.

Key Details

• Extension payment deposited: $34,330.96 into the trust account (extends Termination Date to Feb 6, 2026).
• Extension formula referenced: lesser of (i) $80,000 total or (ii) $0.033 per outstanding public share per monthly extension.
• Promissory Note dated Jan 5, 2026: unsecured, no interest, principal payable upon closing of the Business Combination.
• Conversion right: Payees may convert the note, in whole or in part, into private units at $10.00 per unit (each unit = 1 ordinary share + right to receive 1/5 of a share) by notifying the company at least two business days before closing.

Why It Matters

• The filing shows the company has secured short‑term funding to buy one more month to complete its SPAC merger process. For investors, that reduces immediate liquidation risk tied to the prior Jan 6, 2026 deadline.
• The promissory note creates a direct financial obligation of $34,330.96 that remains outstanding until the business combination closes. If the Payees convert the note into private units, that conversion would increase privately held units and could cause dilution for public shareholders.